Kyntra Bio (NASDAQ:KYNB) Announces Earnings Results

Kyntra Bio (NASDAQ:KYNB) posted its quarterly earnings data on Thursday. The company reported $2.96 EPS for the quarter, FiscalAI reports. The firm had revenue of ($1.47) million for the quarter.

Kyntra Bio Price Performance

Kyntra Bio stock traded down $0.06 during mid-day trading on Thursday, hitting $7.04. The company’s stock had a trading volume of 3,771 shares, compared to its average volume of 22,570. Kyntra Bio has a 52-week low of $6.32 and a 52-week high of $12.60. The company has a market cap of $28.51 million, a PE ratio of 0.17 and a beta of 1.02. The firm’s 50 day moving average is $7.08 and its 200 day moving average is $7.19.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC purchased a new position in Kyntra Bio Inc (NASDAQ:KYNB) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned approximately 0.68% of Kyntra Bio at the end of the most recent reporting period. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on KYNB shares. Wall Street Zen raised shares of Kyntra Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Weiss Ratings restated a “sell (d)” rating on shares of Kyntra Bio in a research report on Tuesday, June 16th. Rodman & Renshaw began coverage on shares of Kyntra Bio in a research note on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Oppenheimer assumed coverage on shares of Kyntra Bio in a research report on Monday, July 6th. They set an “outperform” rating and a $35.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.